An observational study in Lung Cancer, Artifical Intelligence and Surgery for Primary Lung Cancer, sponsored by S. Andrea Hospital. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by S. Andrea Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 300 studies in Lung Neoplasms with a site in Italy — 87 open to participants now, 116 under way, 24 of them phase 3. Lung Neoplasms · Italy.
Among the 300 studies in Lung Neoplasms with a site in Italy, this one is the 78th largest by planned enrollment of the 91 observational ones that give a count, is one of 15 that started in 2026, is one of 91 observational ones, reaches primary completion later than 59 of the 115 other live ones, and was the 299th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →87 of the 300 studies in Lung Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18+ · Healthy volunteers
SystImmune Inc. · Sites in Italy, United States, Australia and 13 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Italy, United States, Belgium and 10 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
300 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 74 · Phase 3 72 · Phase 4 2
First in 1994; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 241 across the 206 interventional studies, 200 across the 91 observational. Of the 153 that completed or were terminated, 56 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 300 have an industry lead sponsor. The 10 most frequent:
S. Andrea Hospital is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
S. Andrea Hospital has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
26 of the studies in Lung Neoplasms with a site in Italy that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 26 to your calendar (.ics) → With an account.
Among the 300 studies in Lung Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study aims to validate an artificial intelligence (AI)-based system for automated three-dimensional (3D) reconstruction of pulmonary anatomy from preoperative chest computed tomography (CT) scans in patients undergoing lung resection.
The AI system will automatically identify and reconstruct relevant pulmonary anatomical structures, including pulmonary arteries, veins, bronchi, lobes, and segments. AI-generated 3D reconstructions will be compared with expert manual 3D reconstructions and with anatomical findings documented during surgery.
The primary objective is to assess the anatomical accuracy of AI-generated 3D reconstructions in identifying surgically relevant bronchovascular anatomy and anatomical variants. Secondary objectives include evaluating accuracy for individual anatomical structures, discrepancies between automated and manual reconstructions, concordance with intraoperative findings, and the time required to generate and review the automated reconstruction.
The study is observational and will not modify the planned surgical procedure or standard patient care.
Patients scheduled for anatomical lung resection who meet the study eligibility criteria will be prospectively enrolled. Preoperative contrast-enhanced chest CT images acquired as part of routine clinical care will be used for 3D reconstruction.
For each patient, an AI-based segmentation system will generate a 3D reconstruction of the relevant pulmonary anatomy, including pulmonary arterial, venous and bronchial structures, as well as lobar and segmental anatomy when applicable. The automated reconstruction will be reviewed without modifying the planned surgical treatment.
AI-generated reconstructions will be compared with expert manual 3D reconstructions and with anatomical findings documented intraoperatively. Particular attention will be given to the identification of surgically relevant bronchovascular branches and anatomical variants.
The primary analysis will assess the proportion of patients in whom the AI-generated reconstruction accurately represents all predefined surgically relevant anatomical structures for the planned resection, without clinically relevant omissions or incorrect structures.
Secondary analyses will assess performance at the individual anatomical-structure level, including arterial, venous and bronchial structures; characterize errors and discrepancies between automated and manual reconstruction; evaluate concordance with intraoperative anatomy; and assess the time required for automated reconstruction and expert review.
The study is a prospective, single-center observational validation study. All diagnostic and therapeutic decisions, including the indication and type of lung resection, will be made according to standard clinical practice independently of study participation.
Adult patients undergoing anatomical lung resection at the Thoracic Surgery Unit of Sant'Andrea University Hospital who have a preoperative contrast-enhanced chest CT scan suitable for AI-based 3D reconstruction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing lung resection who are prospectively enrolled for validation of the AI-based 3D reconstruction system. Preoperative CT images will be processed by the AI system, and the resulting 3D reconstructions will be compared with expert manual reconstruction and intraoperative anatomical findings.
Other: AI-Based 3D Reconstruction
Preoperative contrast-enhanced chest CT images will be processed using an artificial intelligence-based segmentation system to automatically generate three-dimensional reconstructions of pulmonary anatomy, including pulmonary arteries, veins, bronchi, lobes, and segments when applicable. The AI-generated reconstructions will be evaluated against expert manual 3D reconstruction and intraoperative anatomical findings. The AI output will not determine or modify the planned surgical treatment.
Patient-Level Anatomical Accuracy of AI-Generated 3D Reconstruction
Proportion of patients in whom the AI-generated 3D reconstruction correctly represents all predefined surgically relevant pulmonary arterial, venous, and bronchial structures and anatomical variants for the planned lung resection, without clinically relevant omissions or incorrectly represented structures. Accuracy will be assessed by comparison with expert manual 3D reconstruction and intraoperative anatomical findings.
Time frame: From preoperative CT imaging through completion of the surgical procedure
Start is estimated for Nov 2026; primary completion for May 2027, 5 months later.
Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 5 months is below that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
S. Andrea Hospital